# Petmed Express Inc: Form 10-Q for the period ended Dec 31, 2020

- Company: [Petmed Express Inc](/companies/pets.md) (CIK 1040130)
- Form: 10-Q
- Filed: 2021-01-26
- Accepted by EDGAR: Jan 26, 2021, 12:00 ET
- Period: 2020-12-31
- Accession: 0001437749-21-001245
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1040130/000143774921001245/pets20201231_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1040130/000143774921001245/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-10-01 to 2020-12-31 | $65.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months, 2020-04-01 to 2020-12-31 | $237.5m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2020-10-01 to 2020-12-31 | $46.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2020-04-01 to 2020-12-31 | $168.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2020-10-01 to 2020-12-31 | $19.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2020-04-01 to 2020-12-31 | $69.4m | us-gaap:GrossProfit |
| Operating income | 3 months, 2020-10-01 to 2020-12-31 | $9.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-04-01 to 2020-12-31 | $29.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-10-01 to 2020-12-31 | $2.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-04-01 to 2020-12-31 | $6.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-10-01 to 2020-12-31 | $7.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-04-01 to 2020-12-31 | $23.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-10-01 to 2020-12-31 | $0.38 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-04-01 to 2020-12-31 | $1.18 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-10-01 to 2020-12-31 | $0.38 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-04-01 to 2020-12-31 | $1.19 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-10-01 to 2020-12-31 | 20,104,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-04-01 to 2020-12-31 | 20,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-04-01 to 2020-12-31 | $21.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-04-01 to 2020-12-31 | $1.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2020-04-01 to 2020-12-31 | $17.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2020-04-01 to 2020-12-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2020-12-31 | $106.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-12-31 | $141.0m | us-gaap:AssetsCurrent |
| Total assets | at 2020-12-31 | $167.4m | us-gaap:Assets |
| Current liabilities | at 2020-12-31 | $26.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-12-31 | $28.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-12-31 | $139.1m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1040130/000143774921001245/pets20201231_10q.htm

Filed Jan 26, 2021.
Source: SEC EDGAR, the filing index for accession 0001437749-21-001245. Last ingested by Listed: Nov 13, 2026, 14:26 ET. No prices; not investment advice.
